BG
BIO icon

Bellevue Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Bellevue Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,476
Closed -$5.23M – 144
2025
Q1 		$5.23M Sell
21,476
-12,075
-36% -$3.63M 0.12% 87
2024
Q4 		$11M Sell
33,551
-12,600
-27% -$4.28M 0.21% 77
2024
Q3 		$15.4M Sell
46,151
-109,107
-70% -$34.7M 0.25% 80
2024
Q2 		$42.4M Sell
155,258
-1,360
-0.9% -$396K 0.69% 35
2024
Q1 		$54.2M Buy
156,618
+15,471
+11% +$5.09M 0.83% 33
2023
Q4 		$45.6M Buy
141,147
+6,817
+5% +$2.14M 0.7% 47
2023
Q3 		$48.2M Sell
134,330
-203
-0.2% -$78.3K 0.78% 36
2023
Q2 		$51M Buy
134,533
+20,794
+18% +$8.46M 0.73% 44
2023
Q1 		$54.5M Buy
113,739
+2,581
+2% +$1.21M 0.79% 45
2022
Q4 		$46.7M Buy
111,158
+9,340
+9% +$3.77M 0.62% 53
2022
Q3 		$42.5M Buy
101,818
+10,657
+12% +$5.31M 0.61% 48
2022
Q2 		$45.1M Buy
91,161
+19,152
+27% +$9.97M 0.64% 50
2022
Q1 		$40.6M Buy
72,009
+32,326
+81% +$19.5M 0.47% 67
2021
Q4 		$30M Sell
39,683
-6,332
-14% -$4.74M 0.31% 87
2021
Q3 		$34.3M Sell
46,015
-41,286
-47% -$30.9M 0.35% 86
2021
Q2 		$56.2M Sell
87,301
-12,901
-13% -$7.85M 0.55% 63
2021
Q1 		$57.2M Buy
100,202
+35,797
+56% +$21.2M 0.61% 54
2020
Q4 		$37.5M Sell
64,405
-13,781
-18% -$7.85M 0.43% 68
2020
Q3 		$40.3M Sell
78,186
-1,685
-2% -$853K 0.56% 52
2020
Q2 		$36.1M Buy
79,871
+17,498
+28% +$7.72M 0.51% 49
2020
Q1 		$21.9M Buy
62,373
+15,588
+33% +$5.73M 0.42% 62
2019
Q4 		$17.3M Buy
46,785
+40,035
+593% +$14.1M 0.27% 67
2019
Q3 		$2.25M Buy
+6,750
New +$2.2M 0.04% 127

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FPA
First Pacific Advisors El Segundo, California $7.14B AUM 21.51% 1-Year Est. Return

Bellevue Group's BIO Position: Q2 2025 in Review

Bellevue Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 21,476 shares — an estimated $5.23M sold.

Bellevue Group first reported a position in BIO in Q3 2019 and held it in 23 quarters. The position peaked at $57.2M in Q1 2021. 383 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

  • Bellevue Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
  • Bellevue Group sold 21,476 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $5.23M.
  • Bellevue Group first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 23 quarters.
  • Bellevue Group's Bio-Rad Laboratories Class A position peaked at $57.2M in Q1 2021.
  • 383 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.